» Articles » PMID: 20124411

A Mouse Model of Severe Halothane Hepatitis Based on Human Risk Factors

Overview
Specialty Pharmacology
Date 2010 Feb 4
PMID 20124411
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Halothane (2-bromo-2-chloro-1,1,1-trifluoro-ethane) is an inhaled anesthetic that induces severe, idiosyncratic liver injury, i.e., "halothane hepatitis," in approximately 1 in 20,000 human patients. We used known human risk factors (female sex, adult age, and genetics) as well as probable risk factors (fasting and inflammatory stress) to develop a murine model with characteristics of human halothane hepatitis. Female and male BALB/cJ mice treated with halothane developed dose-dependent liver injury within 24 h; however, the liver injury was severe only in females. Livers had extensive centrilobular necrosis, inflammatory cell infiltrate, and steatosis. Fasting rendered mice more sensitive to halothane hepatotoxicity, and 8-week-old female mice were more sensitive than males of the same age or than younger (4-week-old) females. C57BL/6 mice were insensitive to halothane, suggesting a strong genetic predisposition. In halothane-treated females, plasma concentration of tumor necrosis factor-alpha was greater than in males, and neutrophils were recruited to liver more rapidly and to a greater extent. Anti-CD18 serum attenuated halothane-induced liver injury in female mice, suggesting that neutrophil migration, activation, or both are required for injury. Coexposure of halothane-treated male mice to lipopolysaccharide to induce modest inflammatory stress converted their mild hepatotoxic response to a pronounced, female-like response. This is the first animal model of an idiosyncratic adverse drug reaction that is based on human risk factors and produces reproducible, severe hepatitis from halothane exposure with lesions characteristic of human halothane hepatitis. Moreover, these results suggest that a more robust innate immune response underlies the predisposition of female mice to halothane hepatitis.

Citing Articles

Idiosyncratic liver injury induced by bolus combination treatment with emodin and 2,3,5,4'-tetrahydroxystilbene-2---D-glucopyranoside in rats.

Li D, Lyu Y, Song Q, Lai Y, Zuo Z Front Pharmacol. 2022; 13:1017741.

PMID: 36225587 PMC: 9549410. DOI: 10.3389/fphar.2022.1017741.


Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.

Gu R, Liang A, Liao G, To I, Shehu A, Ma X Drug Metab Dispos. 2022; 50(5):646-654.

PMID: 35221288 PMC: 9132098. DOI: 10.1124/dmd.121.000457.


Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Segovia-Zafra A, Di Zeo-Sanchez D, Lopez-Gomez C, Perez-Valdes Z, Garcia-Fuentes E, Andrade R Acta Pharm Sin B. 2022; 11(12):3685-3726.

PMID: 35024301 PMC: 8727925. DOI: 10.1016/j.apsb.2021.11.013.


Preclinical models of acute liver failure: a comprehensive review.

Hefler J, Marfil-Garza B, Pawlick R, Freed D, Karvellas C, Bigam D PeerJ. 2021; 9:e12579.

PMID: 34966588 PMC: 8667744. DOI: 10.7717/peerj.12579.


Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity.

Qin N, Xu G, Wang Y, Zhan X, Gao Y, Wang Z Front Med. 2021; 15(4):594-607.

PMID: 33909257 DOI: 10.1007/s11684-020-0809-2.


References
1.
Qin L, Wang Y, Xu J, Kaneko T, Sato A, Wang P . One-day dietary restriction changes hepatic metabolism and potentiates the hepatotoxicity of carbon tetrachloride and chloroform in rats. Tohoku J Exp Med. 2007; 212(4):379-87. DOI: 10.1620/tjem.212.379. View

2.
INMAN W, Mushin W . Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines. Br Med J. 1974; 1(5896):5-10. PMC: 1632840. DOI: 10.1136/bmj.1.5896.5. View

3.
McLain G, Sipes I, Brown Jr B . An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia. Anesthesiology. 1979; 51(4):321-6. DOI: 10.1097/00000542-197910000-00008. View

4.
Pohl L, Satoh H, Christ D, Kenna J . The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988; 28:367-87. DOI: 10.1146/annurev.pa.28.040188.002055. View

5.
Pohl L, GILLETTE J . A perspective on halothane-induced hepatotoxicity. Anesth Analg. 1982; 61(10):809-11. View